UK schizophrenia drug market is projected to grow at a significant CAGR of around 2.7% during the forecast period. UK has a well-developed healthcare infrastructure with an established mental health facility. National Health Services (NHS) England spends $7.2 million per year on mental health services for ex-service personnel, in addition to the $12.7 billion spending on mental health for the general population, therefore, create significant market growth in the country. Thus, UK has a developed schizophrenia drug market, which is further expected to grow during the forecast period. According to Living with Schizophrenia, UK has almost a quarter of a million people living with schizophrenia.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/uk-schizophrenia-drugs-market
Improved medications and government support towards the treatment of such mental illnesses will contribute to the schizophrenia drug market in UK. Around 10% of all illnesses in the country are represented by schizophrenia. The huge prevalence of schizophrenia in UK has arisen the governmental bodies for the establishment of advanced treatment facilities for mental health, which includes mental hospitals/institutes and pharmaceutical companies. Schizophrenia is a major illness. At any one time, about 220,000 people are being treated for schizophrenia in UK by the NHS, as per Living with Schizophrenia. Therefore, significant growth can be expected in the schizophrenia drug market in UK during the forecast period.
Market Coverage
- The market number available for – 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segments Covered
- By Therapeutic Class
- By Treatment
- Allergan PLC, Catalent, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Co., AstraZeneca PLC, and Johnson & Johnson Services, Inc.
Key questions addressed by the report
- What is the market growth rate during the forecast period?
- Which segment/region dominates the market in the base year?
- Which segment/region will project the fastest growth in the market during the forecast period?
- How COVID-19 will impact the market growth in 2020 and coming years?
- Recovery Timeline
- Deviation from pre-COVID-19
- Most affected region/segment
- Recommendations
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
UK Schizophrenia Drugs Market – Segmentation
By Therapeutic Class
- Second Generation Antipsychotics
- Third Generation Antipsychotics
- Others (First Generation Antipsychotics)
By Treatment
- Oral
- Injectables
A full report of UK Schizophrenia Drugs Market is available at: https://www.omrglobal.com/industry-reports/uk-schizophrenia-drugs-market
